MicroRNAs and Osteolytic Bone Metastasis: The Roles of MicroRNAs in Tumor-Induced Osteoclast Differentiation.

1. Introduction

Cancer is one of the most common causes of death, and bone is the third most common cancer metastatic site following the lung and liver [ 1 ]. Patients with metastasis to bone often present with lesions that can be osteoblastic, osteolytic, or a mixture of the two [ 2 ]. These lesions result from an imbalance between osteoblastic bone formation and osteoclastic bone resorption. Osteoblastic bone metastasis is caused by excessive osteoblast activity relative to osteoclast activity, a characteristic of prostate cancer [ 2 ]. In contrast, osteolytic bone metastasis is caused by excessive osteoclast activity relative to osteoblast activity [ 2 ]. Osteolytic bone metastasis frequently occurs in the later stages of breast, lung, and several other cancers [ 2 , 3 ]. Osteoclasts are hijacked by tumor cells, which break down bone remodeling systems [ 3 , 4 ]. As a result, osteolysis occurs and may cause patients to suffer bone fractures, pain, and hypercalcemia [ 3 , 4 ]. Thus, the quality of life of patients is negatively affected.

Osteoclasts are the only cells that resorb bone [ 5 ]. Osteoclasts are tartrate-resistant acid phosphatase (TRAP)-positive multinucleated giant cells [ 5 , 6 , 7 ], and are formed by the fusion of hematopoietic cells of the monocyte/macrophage lineage. Although osteoclastogenesis is regulated by a variety of hormones, growth factors, and cytokines, macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor κB ligand (RANKL), which are expressed in stromal cells and osteoblasts, are essential for osteoclast differentiation [ 5 , 6 ]. The binding of M-CSF to its receptor, c-Fms, induces the transcription factor c-Fos, whereas the binding of RANKL to its receptor, receptor activator of nuclear factor κB (RANK), leads to the recruitment of TNF-receptor-associated factor 6 (TRAF6), the main adapter molecule of RANK. TRAF6 activates nuclear factor κB (NF-κB) and mitogen-activated kinases, including c-Jun N-terminal kinase (JNK). JNK in turn activates the transcription factor c-Jun [ 8 ]. RANKL/RANK also induces c-Fos to form activator protein-1 (AP-1), a heterodimeric transcription factor, with c-Jun. AP-1 and NF-κB then induce nuclear factor of activated T cell cytoplasmic 1 (NFATc1), a master transcription factor that regulates osteoclast differentiation. NFATc1 works together with other transcription factors such as AP-1, PU.1, and microphthalmia-associated transcription factor (MITF) to induce various osteoclast-specific genes [ 8 ]. Thus, M-CSF and RANKL signaling pathways are crucial for osteoclastogenesis. In contrast, the RANK–RANKL interaction is inhibited by the decoy receptor osteoprotegerin (OPG), a soluble member of the TNF receptor superfamily expressed by stromal cells and osteoblasts [ 9 , 10 ] ( Figure 1 ). Thus, osteoclastogenesis is appropriately regulated in normal physiological conditions.

2. Bone Metastasis

Metastasis to bone is mainly blood-borne [ 1 , 9 , 11 , 12 ]. Tumor cells first detach from the primary lesion and invade the blood vessels. Once in the bloodstream, tumor cells are attracted to preferred sites of metastasis through site-specific interactions between tumor cells and cells in the target organ [ 1 , 11 ]. To metastasize, a tumor cell must gain access to the vasculature from the primary tumor, survive the circulation, escape immune surveillance, and localize in the vasculature of the target organ [ 1 , 13 ]. Most single or clustered tumor cells are thought to expire in the circulation and fail to metastasize because of either anoikis, mechanical trauma, or attack and clearance by the host defense system [ 13 ]. Although circulating tumor cells have been hypothesized to persist as single cells or small cell clusters, there is another pathway of blood-borne metastasis [ 13 , 14 , 15 , 16 ]. Tumor nets are enveloped by vascular endothelial cells and enter the circulation, and tumor emboli may form [ 13 , 14 , 15 ]. Tumor emboli are composed of multicellular tumor nets that are sufficiently large enough to arrest in the target organ, where they thrive and create expansive secondary tumors [ 13 , 14 , 15 ]. In patients with hepatocellular carcinoma, the tumor emboli conserve elements of their primary tumor tissue organization, and are associated with the basement membrane and vascular endothelial cells on the surface [ 13 ]. This architecture can provide an integrated ecosystem that protects the tumor cells from anoikis, mechanical trauma, and immunological engagement during dissemination [ 13 ]. Whether this “invasion-independent metastasis” is involved in bone metastasis is unknown and, considering the abundance of blood in bone tissue, there is a possibility of invasion-independent bone metastasis.

Once tumor cells that metastasize to the skeleton reach the bone marrow, they interact with anatomical entities in contact with the bone called niches. Two different niches exist: the endosteal niche, where stem cells are closely associated with stromal cells and osteoblasts, and the vascular niche, where hematopoietic cells are located [ 12 ].

3. Microenvironment of Osteolytic Lesions

3.1. Growth Factors in the Microenvironment of Osteolytic Lesions

The bone microenvironment comprises osteoblasts, stromal cells, osteoclasts, mineralized bone matrix, hematopoietic cells, and many other cell types [ 11 ]. Bone matrix contains a variety of growth factors, such as insulin-like growth factors (IGFs), transforming growth factor β (TGF-β), fibroblast growth factors, platelet-derived growth factors, and bone morphogenetic proteins [ 1 , 2 , 9 , 11 , 12 , 17 , 18 ]. These bone-derived growth factors are released by osteoclastic bone resorption, and colonization of tumor cells in bone is under the influence of these growth factors. For example, TGF-β is one of the most abundant growth factors in bone matrix [ 11 ]. TGF-β released from bone matrix inhibits T-cell proliferation and activity and the function of natural killer cells, thereby suppressing the immune system [ 17 ]. In addition, TGF-β promotes tumor cell proliferation and survival [ 1 ]. In breast cancer, TGF-β released from the matrix as a result of increased bone resorption can cause tumor cells to produce growth factors such as parathyroid hormone-related protein (PTHrP) and interleukin 11 (IL-11) that can perturb the RANKL/OPG balance, resulting in further osteoclastogenesis and perpetuation of osteolytic disease [ 2 ] ( Figure 2 ).

PTHrP is one of the most important mediators of osteoclast activation [ 1 , 2 , 9 , 11 , 12 , 17 , 18 , 19 ]. More than 90% of patients with breast cancer that has metastasized to bone overexpress PTHrP [ 17 , 19 ]. In addition, PTHrP expression has been determined to be a risk factor for predicting bone metastasis in patients with breast cancer [ 2 ]. In the bone microenvironment, PTHrP is produced by osteoblasts, stromal cells, and cancer cells [ 1 , 2 , 9 , 11 , 12 , 17 , 18 , 19 ]. PTHrP acts on osteoblasts and stromal cells and promotes cellular expression of RANKL, resulting in enhancement of osteoclastogenesis and destruction of bone [ 2 , 9 , 11 , 17 , 18 , 19 ]. Consequently, growth factors are further released from resorbing bone and promote colonization of metastatic tumor cells in bone [ 1 , 2 , 9 , 11 , 17 , 18 , 19 ]. This represents a “vicious circle” between metastatic tumor cells and bone cells ( Figure 2 ).

3.2. Involvement of microRNAs in Tumor-Induced Osteoclast Differentiation

It was recently revealed that microRNAs (miRNAs) play important roles in tumorigenesis and tumor progression [ 20 ]. miRNAs are small, endogenous, noncoding RNAs of approximately 20 to 22 nucleotides in length [ 3 , 5 , 6 , 20 ]. Although the biological functions of most miRNAs are not yet fully understood, they participate in the regulation of cellular differentiation, proliferation, apoptosis, and cancer development [ 5 , 6 , 20 ]. Transcription of miRNA genes yields noncoding transcripts that are subsequently processed through sequential digestion by the RNase III enzymes Drosha and Dicer [ 5 , 6 , 20 ]. The resulting single-stranded mature miRNAs are finally incorporated into an RNA-induced silencing complex (RISC) that contains argonaute (Ago) family proteins [ 5 , 6 , 20 ]. The Ago proteins recruit miRNAs specific to the target mRNAs, and the RISC inhibits the translation of target mRNAs and/or degrades target mRNAs. Thus, miRNAs are involved in post-transcriptional regulation of mRNA function [ 5 , 6 , 20 ].

Recent studies have revealed that miRNAs play critical roles in osteoclastogenesis. We reported that the expression of 52 mature miRNAs differed more than two-fold between untreated cells and cells treated with RANKL during osteoclastogenesis [ 5 ]. As a key factor in osteoclast differentiation, miR-223 regulates nuclear factor I-A and M-CSF receptor levels [ 21 , 22 ]. miR-124 regulates osteoclastogenesis by suppressing NFATc1, a master transcription factor of osteoclast differentiation [ 23 ]. RANKL-induced c-Fos upregulates miR-21, which downregulates the expression of programmed cell death 4 (PDCD4), a negative regulator of osteoclastogenesis [ 24 ]. Overexpression of miR-155 blocks osteoclast differentiation by repressing MITF and PU.1, which are crucial transcription factors for osteoclast differentiation [ 25 ]. These reports are based on murine cell experiments; recent work has begun to uncover the roles of miRNAs in human osteoclast differentiation and function. miR-29b negatively regulates human osteoclastic cell differentiation and function by suppressing c-Fos [ 26 ]. The expression level of miR-503, which directly targets RANK, is markedly lower in progenitors of osteoclasts from postmenopausal women with osteoporosis than in those from postmenopausal healthy women [ 27 ]. The repressive effects on monocyte-specific genes by let-7e/miR-99b/125a/132/212 are crucial for human osteoclast differentiation. These miRNAs are activated directly by NF-κB and exhibit rapid upregulation during osteoclast differentiation. Their inhibition impairs osteoclastogenesis [ 28 ].

It was recently revealed that miRNAs are involved in tumor-induced osteoclast differentiation ( Table 1 ). Ell et al. [ 3 ] reported that five miRNAs (miR-33a, miR-133a, miR-141, miR-190, and miR-219) are significantly downregulated during osteoclastogenesis in both normal physiological conditions and pathophysiological cancer conditions. Ectopic expression of miR-133a, miR-141, and miR-219 strongly inhibited osteoclast differentiation and bone resorption by directly targeting Mitf/Mmp14 , Mitf/Calcr , and Mitf/Traf6 , respectively. Remarkably, miR-141 and miR-219 administered systemically led to a significant decrease in the number of osteoclasts in vivo, and also reduced the metastatic tumor burden in an experimental breast cancer model [ 3 ]. Krzezinski et al. [ 29 ] reported that miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis. The expression level of miR-34a decreases during osteoclastogenesis, and knockdown of miR-34a promotes osteoclast differentiation, while ectopic miR-34a inhibits this differentiation. They also identified transforming growth factor β-induced factor 2 (Tgif2), which is induced by NFATc1 and AP-1 during osteoclast differentiation, as a direct target of miR-34a. miR-34a plays important roles in osteoblast and osteoclast differentiation. Osteoblast differentiation is reduced in miR-34a knockout mice but increased in osteoblastic miR-34a conditional transgenic mice [ 29 ].

The involvement of miRNAs in growth factors of osteolytic lesions has also been shown. TGF-β is released from bone matrix during osteoclastic bone resorption and induces cancer cells to produce osteolytic factors such as IL-11 [ 30 ]. Three miRNAs (miR-204, miR-211, and miR-379) inhibit TGF-β-induced IL-11 production in bone metastatic breast cancer cells [ 30 ]. Kuo et al . [ 31 ] reported that miR-33a functions as a bone metastasis suppressor in lung cancer by targeting PTHrP . miR-33a is downregulated in lung cancer cells, which express high levels of PTHrP. PTHrP enhances osteoclastogenesis by altering the ratio of osteoclastogenesis activator (M-CSF and RANKL)/inhibitor (OPG) produced by osteoblasts. Ectopic miR-33a decreases the induction of lung cancer cells in the production of M-CSF and RANKL in osteoblasts and increases that of OPG in osteoblasts by suppressing PTHrP [ 31 ].

Collectively, specific miRNAs play critical roles in osteoclastogenesis under normal physiological conditions and in tumor-induced osteoclast differentiation.

4. Involvement of Extracellular Vesicles in Osteolytic Bone Metastasis

miRNAs were recently reported to be present in exosomes [ 41 ], a kind of extracellular vesicle (EV), and to function in other cells [ 37 , 42 ]. EVs are lipid bilayered vesicles that exist outside of cells. There are three main types of EVs: apoptotic bodies, microvesicles, and exosomes. Apoptotic bodies are 800 to 5000 nm in diameter and are released by apoptotic cells. Microvesicles are 50 to 1000 nm in diameter and are formed by budding directly from the plasma membrane. Exosomes are 40 to 100 nm in diameter and are derived from multivesicular bodies [ 43 , 44 , 45 ]. Two principal methods of collecting EVs are currently used: with and without ultracentrifugation [ 6 , 45 ]. However, the techniques are inadequate for collecting each type of EV [ 44 , 45 ]. Considering this fact and that the nomenclature of exosomes is confusing [ 46 ], this paper does not use the term “exosomes,” but rather “EVs”. EVs have an important role in cell-to-cell communication via the transfer of miRNAs, mRNAs, proteins, and bioactive lipids to target cells [ 6 , 37 , 41 , 42 , 44 , 47 ]. The secretion of EVs containing miRNAs depends on the cell type, biological condition, and types of miRNAs the cells contain [ 6 , 47 ].

Although osteoclasts play important roles in osteolytic bone metastasis, whether osteoclasts secrete EVs containing miRNAs was unknown until recently. Therefore, we investigated eight miRNAs in the EVs deemed important for osteoclastogenesis in our previous study: let-7e, miR-21, miR-33, miR-155, miR-210, miR-223, miR-378, and miR-1224 [ 6 ]. Of these, the expression levels of miR-378, miR-21, and miR-210 were very high, while no significant expression of miR-33 or miR-1224 was detected [ 6 ]. These results suggest that osteoclasts secrete EVs containing specific miRNAs, but that they do not contain the entire set of intracellular miRNAs. miR-16 and miR-378 are reportedly higher in serum from mice with highly metastatic breast cancer cells and in serum from patients with breast cancer metastasis to bone than in healthy female donors [ 3 ]. miRNAs in serum and plasma are divided into two populations: a vesicle-associated membrane-bound form and a ribonucleoprotein-associated non-membrane-bound form [ 48 ]. Considering that most miR-16 in human serum is present in the ribonucleoprotein-associated non-membrane-bound form [ 48 ], increased levels of miR-16 in the serum of patients with bone metastasis may be of the ribonucleoprotein-associated non-membrane-bound form. Valencia et al . [ 39 ] reported that serum miR-326 could potentially serve as a novel biochemical marker for monitoring bone metastasis from lung cancer. They reported that the level of miR-326 may not only reflect tumor-autonomous release, but also host-derived factors acting on tumor cells, because miR-326 has been implicated in lymphocytic differentiation, chemoresistance, and tumor-suppressive activities [ 39 ].

While these reports are important, the function of miRNAs and EVs was not mentioned. Several reports suggest the involvement of EVs in osteolytic bone metastasis. One suggests that forced expression of miR-192 in EVs of highly metastatic lung cancer cells decreases osteolytic lesions in a mouse model. miR-192 in the EVs is transferred to endothelial cells and inhibits angiogenesis [ 37 ]. A second study showed that EVs from multiple myeloma cells increase CXC-chemokine receptor 4 expression in pre-osteoclasts and modulate cell migration. EVs derived from the serum of patients with multiple myeloma promote osteoclast differentiation [ 49 ]. A third report showed that EVs from parathyroid hormone (PTH)-treated UAMS-32P cells from a stromal/osteoblastic cell line promote osteoclast differentiation. The EVs containing RANK, RANKL receptor, and RANKL antibody treatment inhibited osteoclastogenesis [ 50 ]. Thus, EVs from PTH-treated osteoblastic cells promote osteoclast differentiation via RANK/RANKL signaling. Given that both PTH and PTHrP bind to the same receptor, the PTH/PTHrP receptor, PTHrP from tumor cells may stimulate stromal/osteoblastic cells to secrete EVs, and thus the EVs may induce osteoclast differentiation ( Figure 2 ).

5. Conclusions

Bone metastasis is a highly complicated process, and the bone microenvironment contains numerous physical factors. Although a single miRNA generally represses the production of hundreds of proteins, the repression is typically mild [ 51 ]. Considering this mild effect, it may be necessary to combine miRNA-based and traditional routine therapies to successfully treat bone metastasis. For example, combination treatments with miRNAs and currently approved osteoclast-targeting agents, such as bisphosphonates and the anti-RANKL antibody denosumab, might provide enhanced clinical efficiency. Although it may be a long way to the use of miRNAs as therapeutic agents, we anticipate that this new therapeutic target for bone metastasis opens another door to cancer treatment.

Acknowledgments

This work was supported, in part, by the grant from the Scientific Research (C) (No. 26462853) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Conflicts of Interest

The author declares no conflict of interest.

References

1. Krzeszinski J.Y. Wan Y. New therapeutic targets for cancer bone metastasis Trends Pharmacol. Sci. 2015 36 360 373 10.1016/j.tips.2015.04.006 25962679 PMC4461455

2. Browne G. Taipaleenmaki H. Stein G.S. Stein J.L. Lian J.B. MicroRNAs in the control of metastatic bone disease Trends Endocrinol. Metab. 2014 25 320 327 10.1016/j.tem.2014.03.014 24811921 PMC4075094

3. Ell B. Mercatali L. Ibrahim T. Campbell N. Schwarzenbach H. Pantel K. Amadori D. Kang Y. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis Cancer Cell 2013 24 542 556 10.1016/j.ccr.2013.09.008 24135284 PMC3832956

4. Waning D.L. Mohammad K.S. Guise T.A. Cancer-associated osteoclast differentiation takes a good look in the miR(NA)ror Cancer Cell 2013 24 407 409 10.1016/j.ccr.2013.10.001 24135278 PMC3897244

5. Kagiya T. Nakamura S. Expression profiling of microRNAs in RAW264.7 cells treated with a combination of tumor necrosis factor alpha and RANKL during osteoclast differentiation J. Periodontal Res. 2013 48 373 385 10.1111/jre.12017 23078176

6. Kagiya T. Taira M. Expression of MicroRNAs in the Extracellular Microvesicles of Murine Osteoclasts J. Oral Tissue Engin. 2013 10 142 150

7. Itzstein C. Coxon F.P. Rogers M.J. The regulation of osteoclast function and bone resorption by small GTPases Small GTPases 2011 2 117 130 10.4161/sgtp.2.3.16453 21776413 PMC3136942

8. Nakashima T. Takayanagi H. Osteoclasts and the immune system J. Bone Miner. Metab. 2009 27 519 529 10.1007/s00774-009-0089-z 19455385

9. Weilbaecher K.N. Guise T.A. McCauley L.K. Cancer to bone: a fatal attraction Nat. Rev. Cancer 2011 11 411 425 10.1038/nrc3055 21593787 PMC3666847

10. Jones D.H. Nakashima T. Sanchez O.H. Kozieradzki I. Komarova S.V. Sarosi I. Morony S. Rubin E. Sarao R. Hojilla C.V. Regulation of cancer cell migration and bone metastasis by RANKL Nature 2006 440 692 696 10.1038/nature04524 16572175

11. Kingsley L.A. Fournier P.G. Chirgwin J.M. Guise T.A. Molecular biology of bone metastasis Mol. Cancer Ther. 2007 6 2609 2617 10.1158/1535-7163.MCT-07-0234 17938257

12. Croset M. Santini D. Iuliani M. Fioramonti M. Zoccoli A. Vincenzi B. Tonini G. Pantano F. MicroRNAs and bone metastasis: a new challenge Molecules 2014 19 10115 10128 10.3390/molecules190710115 25019555 PMC6271587

13. Sugino T. Yamaguchi T. Hoshi N. Kusakabe T. Ogura G. Goodison S. Suzuki T. Sinusoidal tumor angiogenesis is a key component in hepatocellular carcinoma metastasis Clin. Exp. Metastasis 2008 25 835 841 10.1007/s10585-008-9199-6 18712609 PMC3431607

14. Sugino T. Kusakabe T. Hoshi N. Yamaguchi T. Kawaguchi T. Goodison S. Sekimata M. Homma Y. Suzuki T. An invasion-independent pathway of blood-borne metastasis: a new murine mammary tumor model Am. J. Pathol. 2002 160 1973 1980 10.1016/S0002-9440(10)61147-9 12057902 PMC1850839

15. Kats-Ugurlu G. Roodink I. de Weijert M. Tiemessen D. Maass C. Verrijp K. van der Laak J. de Waal R. Mulders P. Oosterwijk E. Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma J. Pathol. 2009 219 287 293 10.1002/path.2613 19731255

16. Al-Mehdi A.B. Tozawa K. Fisher A.B. Shientag L. Lee A. Muschel R.J. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis Nat. Med. 2000 6 100 102 10613833 10.1038/71429

17. Suva L.J. Washam C. Nicholas R.W. Griffin R.J. Bone metastasis: mechanisms and therapeutic opportunities Nat. Rev. Endocrinol. 2011 7 208 218 10.1038/nrendo.2010.227 21200394 PMC3134309

18. Hiraga T. Myoui A. Hashimoto N. Sasaki A. Hata K. Morita Y. Yoshikawa H. Rosen C.J. Mundy G.R. Yoneda T. Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases Cancer Res. 2012 72 4238 4249 10.1158/0008-5472.CAN-11-3061 22738911 PMC3438359

19. Martin T.J. Manipulating the environment of cancer cells in bone: a novel therapeutic approach J. Clin. Invest. 2002 110 1399 1401 10.1172/JCI0217124 12438435 PMC151823

20. Takahashi R.U. Miyazaki H. Ochiya T. The Roles of MicroRNAs in Breast Cancer Cancers 2015 7 598 616 10.3390/cancers7020598 25860815 PMC4491673

21. Sugatani T. Hruska K.A. MicroRNA-223 is a key factor in osteoclast differentiation J. Cell Biochem. 2007 101 996 999 10.1002/jcb.21335 17471500

22. Sugatani T. Hruska K.A. Impaired micro-RNA pathways diminish osteoclast differentiation and function J. Biol. Chem. 2009 284 4667 4678 10.1074/jbc.M805777200 19059913 PMC2640963

23. Lee Y. Kim H.J. Park C.K. Kim Y.G. Lee H.J. Kim J.Y. Kim H.H. MicroRNA-124 regulates osteoclast differentiation Bone 2013 56 383 389 10.1016/j.bone.2013.07.007 23867221

24. Sugatani T. Vacher J. Hruska K.A. A microRNA expression signature of osteoclastogenesis Blood 2011 117 3648 3657 10.1182/blood-2010-10-311415 21273303 PMC3072882

25. Mann M. Barad O. Agami R. Geiger B. Hornstein E. miRNA-based mechanism for the commitment of multipotent progenitors to a single cellular fate Proc. Natl. Acad. Sci. USA 2010 107 15804 15809 10.1073/pnas.0915022107 20720163 PMC2936650

26. Rossi M. Pitari M.R. Amodio N. Di Martino M.T. Conforti F. Leone E. Botta C. Paolino F.M. Del Giudice T. Iuliano E. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease J. Cell Physiol. 2013 228 1506 1515 10.1002/jcp.24306 23254643

27. Chen C. Cheng P. Xie H. Zhou H.D. Wu X.P. Liao E.Y. Luo X.H. MiR-503 regulates osteoclastogenesis via targeting RANK J. Bone Miner. Res. 2014 29 338 347 10.1002/jbmr.2032 23821519

28. De la Rica L. Garcia-Gomez A. Comet N.R. Rodriguez-Ubreva J. Ciudad L. Vento-Tormo R. Company C. Alvarez-Errico D. Garcia M. Gomez-Vaquero C. NF-kappaB-direct activation of microRNAs with repressive effects on monocyte-specific genes is critical for osteoclast differentiation Genome Biol. 2015 16 2 10.1186/s13059-014-0561-5 25601191 PMC4290566

29. Krzeszinski J.Y. Wei W. Huynh H. Jin Z. Wang X. Chang T.C. Xie X.J. He L. Mangala L.S. Lopez-Berestein G. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2 Nature 2014 512 431 435 10.1038/nature13375 25043055 PMC4149606

30. Pollari S. Leivonen S.K. Perala M. Fey V. Kakonen S.M. Kallioniemi O. Identification of microRNAs inhibiting TGF-beta-induced IL-11 production in bone metastatic breast cancer cells PLoS One 2012 7 e37361 10.1371/journal.pone.0037361 22629385 PMC3357420

31. Kuo P.L. Liao S.H. Hung J.Y. Huang M.S. Hsu Y.L. MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein Biochim. Biophys. Acta. 2013 1830 3756 3766 10.1016/j.bbagen.2013.02.022 23458685

32. O’Day E. Lal A. MicroRNAs and their target gene networks in breast cancer Breast Cancer Res. 2010 12 201 10.1186/bcr2484 20346098 PMC2879559

33. Valastyan S. Weinberg R.A. miR-31: a crucial overseer of tumor metastasis and other emerging roles Cell Cycle 2010 9 2124 2129 10.4161/cc.9.11.11843 20505365

34. Mizoguchi F. Murakami Y. Saito T. Miyasaka N. Kohsaka H. miR-31 controls osteoclast formation and bone resorption by targeting RhoA Arthritis Res. Ther. 2013 15 R102 10.1186/ar4282 24004633 PMC3978447

35. Guo L.J. Liao L. Yang L. Li Y. Jiang T.J. MiR-125a TNF receptor-associated factor 6 to inhibit osteoclastogenesis Exp. Cell Res. 2014 321 142 152 10.1016/j.yexcr.2013.12.001 24360988

36. Wang J. Yu F. Jia X. Iwanowycz S. Wang Y. Huang S. Ai W. Fan D. MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth Int. J. Cancer 2015 136 E602 E613 10.1002/ijc.29151 25143000 PMC4289468

37. Valencia K. Luis-Ravelo D. Bovy N. Anton I. Martinez-Canarias S. Zandueta C. Ormazabal C. Struman I. Tabruyn S. Rebmann V. miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization Mol. Oncol. 2014 8 689 703 10.1016/j.molonc.2014.01.012 24593875 PMC5528646

38. Lim P.K. Bliss S.A. Patel S.A. Taborga M. Dave M.A. Gregory L.A. Greco S.J. Bryan M. Patel P.S. Rameshwar P. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells Cancer Res. 2011 71 1550 1560 10.1158/0008-5472.CAN-10-2372 21343399

39. Valencia K. Martin-Fernandez M. Zandueta C. Ormazabal C. Martinez-Canarias S. Bandres E. de la Piedra C. Lecanda F. miR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis Bone 2013 52 532 539 10.1016/j.bone.2012.10.033 23142363

40. Lee D.Y. Deng Z. Wang C.H. Yang B.B. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression Proc. Natl Acad Sci USA 2007 104 20350 20355 10.1073/pnas.0706901104 18077375 PMC2154434

41. Valadi H. Ekstrom K. Bossios A. Sjostrand M. Lee J.J. Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells Nat. Cell. Biol. 2007 9 654 659 10.1038/ncb1596 17486113

42. Kosaka N. Iguchi H. Yoshioka Y. Takeshita F. Matsuki Y. Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells J. Biol. Chem. 2010 285 17442 17452 10.1074/jbc.M110.107821 20353945 PMC2878508

43. Carandini T. Colombo F. Finardi A. Casella G. Garzetti L. Verderio C. Furlan R. Microvesicles: What is the Role in Multiple Sclerosis? Front Neurol. 2015 6 111 10.3389/fneur.2015.00111 26074867 PMC4443736

44. Nishida-Aoki N. Ochiya T. Interactions between cancer cells and normal cells via miRNAs in extracellular vesicles Cell. Mol. Life Sci. 2015 72 1849 1861 10.1007/s00018-014-1811-0 25563488 PMC4412282

45. Crescitelli R. Lasser C. Szabo T.G. Kittel A. Eldh M. Dianzani I. Buzas E.I. Lotvall J. Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes J. Extracell Vesicles 2013 2 20677 10.3402/jev.v2i0.20677 24223256 PMC3823106

46. Gould S.J. Raposo G. As we wait: coping with an imperfect nomenclature for extracellular vesicles J. Extracell Vesicles 2013 2 20389 10.3402/jev.v2i0.20389 24009890 PMC3760635

47. Kagiya T. Taira M. A New Application for Microarrays: Analysis of Global MicroRNA Expression Profiles in the Extracellular Microvesicles of Human Macrophage-like Cells Microarrays: Principles, Applications and Technologies Rogers J.V. Nova Science Publishers New York, NY, USA 2014 69 80

48. Arroyo J.D. Chevillet J.R. Kroh E.M. Ruf I.K. Pritchard C.C. Gibson D.F. Mitchell P.S. Bennett C.F. Pogosova-Agadjanyan E.L. Stirewalt D.L. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma Proc. Natl. Acad. Sci. USA 2011 108 5003 5008 10.1073/pnas.1019055108 21383194 PMC3064324

49. Raimondi L. De Luca A. Amodio N. Manno M. Raccosta S. Taverna S. Bellavia D. Naselli F. Fontana S. Schillaci O. Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation Oncotarget 2015 6 13772 13789 25944696 10.18632/oncotarget.3830 PMC4537049

50. Deng L. Wang Y. Peng Y. Wu Y. Ding Y. Jiang Y. Shen Z. Fu Q. Osteoblast-derived microvesicles: A novel mechanism for communication between osteoblasts and osteoclasts Bone 2015 79 37 42 10.1016/j.bone.2015.05.022 26013558

51. Selbach M. Schwanhausser B. Thierfelder N. Fang Z. Khanin R. Rajewsky N. Widespread changes in protein synthesis induced by microRNAs Nature 2008 455 58 63 10.1038/nature07228 18668040